Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan and fludarabine with or without TBI for MDS or AML transplant conditioning
NCT01894477Phase 2Unknown
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2013
- Primary completion
- Jan 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Fred Hutchinson Cancer Center. Status: unknown.
02
Drugs
treosulfan
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT01894477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01894477.